(Reuters)-Australia’s biotechnology giant CSL Ltd is in exclusive talks to buy Vifor Pharma for an A $ 10 billion ($ 7.1 billion) deal, Australia reported Thursday. It exceeded the stock by more than 17%.
The newspaper reported in March that CSL’s acquisition of Vifor may be underway. Negotiations have been underway since then, according to the latest report.
Vifor Pharma and CSL said in separate statements that they would not comment on speculation.
At the top of the Swiss midcap index, Vifor’s share price rose 21% and Thursday’s CSL fell 1.3%.
($ 1 = 1.4083 Australian dollars)
Fusion media Alternatively, anyone involved in Fusion Media will not be liable for any loss or damage resulting from reliance on the data, quotes, charts, trading signals and other information contained on this website. Be fully informed about the risks and costs associated with financial market transactions. This is one of the most risky forms of investment possible.
Australian CSL under exclusive negotiations to acquire Swiss Vifor Pharma
Source link Australian CSL under exclusive negotiations to acquire Swiss Vifor Pharma